Press Release Details

Kiniksa Pharmaceuticals, Ltd. Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares


HAMILTON, Bermuda, May 18, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today the closing of its public offering of 2,760,000 of its Class A common shares at a public offering price of $18.25 per share, which includes the exercise in full by the underwriters of their option to purchase additional shares. The gross proceeds to Kiniksa from this offering and its previously announced concurrent private placement were approximately $80 million, before deducting fees and offering expenses payable by Kiniksa.

Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and BofA Securities acted as joint book-running managers for the public offering. Wedbush Securities Inc. and JMP Securities LLC acted as co-managers for the public offering.

A shelf registration statement related to the Class A common shares (including a prospectus) was filed with the U.S. Securities and Exchange Commission (the “SEC”) and was declared effective on June 10, 2019. The public offering was made only by means of a prospectus supplement and the accompanying prospectus which form a part of the effective shelf registration statement. Copies of the final prospectus supplement relating to the public offering and the accompanying prospectus may be obtained by visiting EDGAR on the SEC’s website located at, or by contacting Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, New York 10282, or by telephone at (866) 471-2526, or via email at; J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone: (866) 803-9204, or via email at; and BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255, Attention: Prospectus Department, or via email at

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Kiniksa

Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s clinical stage product candidates, rilonacept, mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These pipeline assets are designed to modulate immunological signaling pathways that are implicated across a spectrum of diseases.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.

These forward-looking statements are based on management’s current plans, estimates or expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including without limitation, risks and uncertainties related to global economic or market conditions, volatility in the share price of our Class A common shares, and changes in our operating plan or funding requirements.

These and other important factors discussed under the caption “Risk Factors” in our Form 10-Q for the three months ended March 31, 2020, the final prospectus supplement related to the public offering and the accompanying prospectus, and our other reports subsequently filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s plans, estimates or expectations as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Every Second Counts!™

Kiniksa Investor and Media Contact
Mark Ragosa | | (781) 430-8289

KINIKSA _2c_final - Copy.jpg

Source: Kiniksa Pharmaceuticals, Ltd.